骨髓 miR-10a 过表达与遗传事件相关，但不影响急性髓系白血病的临床结局。
Bone marrow miR-10a overexpression is associated with genetic events but not affects clinical outcome in acute myeloid leukemia.
机构信息
Department of Hematology, Affiliated People's Hospital of Jiangsu University, Zhenjiang, Jiangsu, People's Republic of China; The Key Lab of Precision Diagnosis and Treatment of Zhenjiang City, Zhenjiang, Jiangsu, People's Republic of China; School of Medicine, Jiangsu University, Zhenjiang, Jiangsu, People's Republic of China.
Laboratory Center, Affiliated People's Hospital of Jiangsu University, Zhenjiang, Jiangsu, People's Republic of China; The Key Lab of Precision Diagnosis and Treatment of Zhenjiang City, Zhenjiang, Jiangsu, People's Republic of China.
出版信息
Pathol Res Pract. 2018 Jan;214(1):169-173. doi: 10.1016/j.prp.2017.11.019. Epub 2017 Dec 5.
BACKGROUND
Accumulating studies have linked the disruptions of microRNA-10 (miR-10) to acute myeloid leukemia (AML) with NPM1 mutation. However, miR-10 expression and its clinical implication in AML remain poorly defined. Although a recent report showed high serum level of miR-10a was associated with adverse prognosis in AML, herein, we found bone marrow (BM) miR-10 overexpression was not a prognostic biomarker in AML.
METHODS
BM miR-10 expression was examined by real-time quantitative PCR in BM mononuclear cells in 115 de novo AML patients and 45 controls.
RESULTS
BM miR-10 (miR-10a/b) expression was significantly up-regulated in AML patients, and was positively correlated with each other. Overexpression of miR-10a was associated with lower percentage of BM blasts, whereas miR-10b overexpression tended to correlate with higher percentage of BM blasts. Importantly, miR-10a overexpression was significantly associated with FAB-M3/t(15;17) subtypes and NPM1 mutation, meanwhile, overexpression of miR-10b was correlated with NPM1 and DNMT3A mutations. However, miR-10a/b overexpression was not associated with complete remission rate, and did not have an impact on both leukemia free survival and overall survival time in non-M3 AML patients without NPM1 mutation.
CONCLUSIONS
BM miR-10 overexpression is associated with genetic events but not affects clinical outcome in AML.
背景
越来越多的研究表明，miR-10 的失调与 NPM1 突变的急性髓系白血病（AML）有关。然而，miR-10 在 AML 中的表达及其临床意义仍未得到明确界定。尽管最近的一份报告表明，高血清 miR-10a 水平与 AML 的不良预后相关，但在此，我们发现骨髓（BM）miR-10 过表达不是 AML 的预后生物标志物。
方法
通过实时定量 PCR 检测 115 例初诊 AML 患者和 45 例对照者 BM 单个核细胞中的 BM miR-10 表达。
结果
AML 患者的 BM miR-10（miR-10a/b）表达显著上调，且彼此呈正相关。miR-10a 的过表达与 BM 原始细胞比例降低相关，而 miR-10b 的过表达则与 BM 原始细胞比例升高相关。重要的是，miR-10a 的过表达与 FAB-M3/t(15;17)亚型和 NPM1 突变显著相关，而 miR-10b 的过表达与 NPM1 和 DNMT3A 突变相关。然而，miR-10a/b 的过表达与完全缓解率无关，且在无 NPM1 突变的非 M3 AML 患者中，对无白血病生存时间和总生存时间均无影响。
结论
BM miR-10 过表达与遗传事件相关，但不影响 AML 的临床结局。
Zotero 插件